62741
document
Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation : a randomized trial . To evaluate the effect of the different doses of antithymocyte globulin ( ATG ) on the incidence of acute GVHD among patients receiving hematopoietic SCT without ex vivo T-cell-depletion from haploidentical donors , 224 patients with standard-risk hematological malignancy were randomized in this study . One hundred and twelve patients received 6 mg/kg ATG , whereas the remaining patients received 10 mg/kg ATG . This study was registered at http : //www.chictr.org as No . ChiCTR-TRC-11001761 . The incidence of grade III-IV acute GVHD was higher in the ATG-6 group ( 16.1 % , 95 % confidence interval ( CI ) , 9.1-23.1 % ) than in the ATG-10 group ( 4.5 % , CI , 0.7-8.3 % , P=0.005 , 95 % CI for the difference , -19.4 % to -3.8 % ) . EBV reactivation occurred more frequently in the ATG-10 group ( 25.3 % , 17.1-33.5 % ) than in the ATG-6 group ( 9.6 % ( 4.0-15.2 % ) , P=0.001 ) . The 1-year disease-free survival rates were 84.3 % ( 77.3-91.3 % ) and 86.0 % ( 79.2-92.8 % ) for the ATG-6 group and ATG-10 groups , respectively ( P=0.88 ) . In conclusion , although 6 mg/kg ATG applied in haploidentical transplantation decreased the risk of EBV reactivation compared with 10 mg/kg ATG , this treatment exposes patients to a higher risk for severe acute GVHD .
62742
Intervention_Pharmacological
antithymocyte globulin
62743
Intervention_Pharmacological
antithymocyte globulin ( ATG )
62744
Participant_Condition
standard-risk disease
62745
Participant_Condition
haploidentical transplantation
62746
Participant_Sample-size
224 patients
62747
Participant_Condition
standard-risk hematological malignancy
62748
Participant_Sample-size
One hundred and twelve patients